Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial).

Jun MasudaHitomi SakaiJunji TsurutaniYuko TanabeNorikazu MasudaTsutomu IwasaMasato TakahashiManabu FutamuraKoji MatsumotoKenjiro AogiHiroji IwataMari HosonagaToru MukoharaKiyoshi YoshimuraChiyo K ImamuraSakiko MiuraToshiko YamochiHidetaka KawabataHiroyuki YasojimaNobumoto TomiokaKenichi YoshimuraToshimi Takano

Published in: Journal for immunotherapy of cancer (2023)

JapicCTI-194782, jRCT2080224706, UMIN000036970.

Keyphrases

phase ii study
metastatic breast cancer
open label
phase iii
phase ii
locally advanced
study protocol
clinical trial
placebo controlled
randomized controlled trial
squamous cell carcinoma
stem cells
bone marrow
smoking cessation